CAPF reform of economic evaluation of medicines in Spain (three-phase reform proposals)
The CAPF proposed a three-phase reform to improve how Spain evaluates the cost-effectiveness and budget impact of new medicines. It makes it mandatory for drug companies to submit economic evaluations, sets up a government-led review process, and links the results to pricing and reimbursement decisions. The goal is to make drug funding decisions more transparent, efficient, and sustainable.
At a glance
Use when
Designing or reforming national pharmaceutical reimbursement systems, especially when seeking to strengthen the role of economic evidence in pricing and funding decisions.
Avoid when
In settings with limited institutional capacity for centralized economic evaluation or where rapid drug access is prioritized over comprehensive assessment.
Inputs
Mandatory economic evaluations and budget impact analyses submitted by pharmaceutical applicants for new medicines.
Outputs
Assessed and standardized economic evidence used to inform decisions on drug pricing, reimbursement, positioning, and financing within the Spanish NHS.
How it works
The Advisory Committee for Pharmaceutical Financing (CAPF) in Spain proposed a three-phase reform (2019–2024) to strengthen the integration of economic evaluation (EE) and budget impact analysis (BIA) into pharmaceutical decision-making within the National Health System (NHS). Phase 1 mandates submission of EE and BIA by applicants for new medicines. Phase 2 establishes centralized assessment coordinated by the Directorate-General for Pharmaceuticals. Phase 3 implements the use of these assessments in pricing, positioning, and financing decisions. The reform emphasizes regulatory improvement, transparency, methodological standardization, and the development of official NHS guidance. A dynamic appraisal system is proposed to support ongoing evaluation and adaptability. The framework aims to institutionalize efficiency criteria in pharmaceutical policy and enhance the methodological rigor and transparency of submissions.
- HTA domains
- Costs & Economic Evaluation, Organisational aspects
- Assumptions
- Applicants can produce reliable and comparable economic evaluations; centralized assessment improves consistency and objectivity; decision-makers will use economic evidence to prioritize efficiency and sustainability.
- Strengths
- Introduces mandatory and standardized economic evaluations,Enhances transparency and methodological quality,Centralizes assessment to reduce variability,Links evidence directly to decision-making,Promotes long-term sustainability of pharmaceutical spending
- Limitations
- Dependent on the capacity and resources of the Directorate-General for Pharmaceuticals,Potential delays in market access due to added evaluation steps,Risk of inconsistent application across regions in a decentralized health system,Relies on accurate and unbiased input from pharmaceutical companies
- Also known as
- CAPF three-phase reform, Spanish pharmaceutical economic evaluation reform, CAPF EE/BIA reform
Questions this answers
- › How can economic evaluations be systematically integrated into medicine reimbursement decisions in Spain?
- › What structural changes improve the transparency and quality of pharmaceutical economic evaluations?
- › How can budget impact and cost-effectiveness analyses inform drug pricing and financing?
- › What role should centralized agencies play in assessing economic submissions for medicines?
- › How can dynamic and methodologically sound evaluation systems support sustainable pharmaceutical policy?
- › What steps ensure that efficiency is embedded in national drug funding decisions?
References & sources
Similar by meaning
- Guideline for the economic evaluation of medicines (CAPF / Spanish NHS Advisory Committee for Pharmaceutical Financing)
- Spanish recommendations on economic evaluation of health technologies (López-Bastida guideline)
- Revised methods guide for economic evaluation studies of health technologies in Portugal
- AIFA Guidelines for the economic evaluation of health technologies (P&R dossier, Chapter 9)
- INFARMED Methodology for Pharmacotherapeutic Assessment of Health Technologies (METOD-AFT)
Beta record. Generated from the primary source via AI extraction and independent audit, pending final human review.